lecanemab

(Newser) - Last summer, the Food and Drug Administration gave the thumbs-up to Leqembi, the first drug shown to slow the progression of Alzheimer's disease. Now, almost a year to the day after that move, the government agency has greenlit a second drug: Eli Lilly's donanemab, sold under the brand...

(Newser) - A drug found to slow the progression of Alzheimer's disease received federal approval on Friday for patients dealing with mild impairment. Lecanemab was effective in clinical trials but raised safety concerns, and experts say the benefits are not overwhelming, NBC News reports. Nevertheless, the FDA fast-tracked its approval, not...

(Newser) - Last year, the FDA approved aducanumab , marketed as Aduhelm , a controversial drug made by Biogen and its Japanese partner Eisai to treat Alzheimer's. Things didn't go well, though, with expert opposition to the costly medication and a final death blow to its place in the market after Medicare...